Payment overview · 2025
General Payments
$3,880.15
80 reported records · 27 companies
Healthcare provider profile · identity verified
Tony Lu, M.D.
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · SUGAR LAND, TX · NPI 1265876338
Verified facts
What the public records show
CMS Open Payments records show Tony Lu, M.D. received $3,880.15 in general payments during 2025 across 80 reported records.
Boston Scientific Corporation accounted for 27.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $1,074.19 | 27.7% | 12 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $731.12 | 18.8% | 12 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $255.81 | 6.6% | 8 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $255.07 | 6.6% | 5 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $211.53 | 5.5% | 9 | 2025 |
| Aroa Biosurgery Incorporated | Unresolved — no canonical attribution shown | $194.93 | 5.0% | 7 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$183.47 | 4.7% | 2 | 2025 |
| Royal Biologics, Inc. | Unresolved — no canonical attribution shown | $172.79 | 4.5% | 1 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $171.11 | 4.4% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $169.72 | 4.4% | 2 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $53.58 | 1.4% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $49.44 | 1.3% | 2 | 2025 |
| Ossur Americas, Inc. | Unresolved — no canonical attribution shown | $46.05 | 1.2% | 2 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $35.09 | 0.9% | 2 | 2025 |
| Sanara MedTech Inc. | Unresolved — no canonical attribution shown | $30.89 | 0.8% | 1 | 2025 |
| ARGON MEDICAL DEVICES, INC. | Unresolved — no canonical attribution shown | $29.59 | 0.8% | 2 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $26.44 | 0.7% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $24.83 | 0.6% | 1 | 2025 |
| Dilon Technologies, Inc. | Unresolved — no canonical attribution shown | $23.06 | 0.6% | 1 | 2025 |
| Argentum Medical | Unresolved — no canonical attribution shown | $22.00 | 0.6% | 1 | 2025 |
| AltaThera Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $21.35 | 0.6% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $20.89 | 0.5% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $20.32 | 0.5% | 1 | 2025 |
| Pacira Pharmaceuticals Incorporated | Unresolved — no canonical attribution shown | $18.54 | 0.5% | 1 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $18.06 | 0.5% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $16.63 | 0.4% | 1 | 2025 |
| Alafair Biosciences, Inc. | Unresolved — no canonical attribution shown | $3.65 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,065.61 | 77 |
| Consulting Fee | $781.25 | 1 |
| Entertainment | $22.00 | 1 |
| Travel and Lodging | $11.29 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AngioJet Ultra 5000A Normalized: angiojet ultra 5000a |
Device | Boston Scientific Corporation | $895.45 | 4 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $512.26 | 3 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $255.81 | 8 | 2025 |
Source payment records
|
|||||
| ZILVER PTX Normalized: zilver ptx |
Device | Cook Medical LLC | $226.91 | 4 | 2025 |
Source payment records
|
|||||
| TREO ABDOMINAL STENT-GRAFT SYSTEM Normalized: treo abdominal stent graft system |
Device | Bolton Medical Inc | $211.53 | 9 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $183.47 | 2 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $171.11 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $90.55 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $76.97 | 6 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $76.17 | 3 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $76.17 | 3 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $53.58 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $53.58 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Stent Normalized: enroute transcarotid stent |
Device | Boston Scientific Corporation | $39.25 | 2 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $38.27 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy System Normalized: pounce thrombectomy system |
Device | Surmodics, Inc. | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| Sublime 014 Rx PTA Balloon Dilatation Catheter Normalized: sublime 014 rx pta balloon dilatation catheter |
Device | Surmodics, Inc. | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| Sublime Microcatheter, 018, 200cm, Straight Normalized: sublime microcatheter 018 200cm straight |
Device | Surmodics, Inc. | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| CellerateRX Normalized: celleraterx |
Device | Sanara MedTech Inc. | $30.89 | 1 | 2025 |
Source payment records
|
|||||
| CLOT MANAGEMENT Normalized: clot management |
Device | ARGON MEDICAL DEVICES, INC. | $29.59 | 2 | 2025 |
Source payment records
|
|||||
| ZENITH SPIRAL-Z Normalized: zenith spiral z |
Device | Cook Medical LLC | $28.16 | 1 | 2025 |
Source payment records
|
|||||
| ENHANCE Transcarotid Peripheral Access Kit Normalized: enhance transcarotid peripheral access kit |
Device | Boston Scientific Corporation | $27.03 | 1 | 2025 |
Source payment records
|
|||||
| Pico 14 Normalized: pico 14 |
Device | Smith+Nephew, Inc. | $27.00 | 1 | 2025 |
Source payment records
|
|||||
| ARTEGRAFT VASCULAR GRAFT Normalized: artegraft vascular graft |
Device | LeMaitre Vascular, Inc. | $26.44 | 1 | 2025 |
Source payment records
|
|||||
| RESONATE EL ICD VR Normalized: resonate el icd vr |
Device | Boston Scientific Corporation | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| HEMOBLAST BELLOWS Normalized: hemoblast bellows |
Device | Dilon Technologies, Inc. | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| Versajet Normalized: versajet |
Device | Smith+Nephew, Inc. | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| Sotalol Hydrochloride Normalized: sotalol hydrochloride |
Drug | AltaThera Pharmaceuticals LLC | $21.35 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| Exparel Normalized: exparel |
Drug | Pacira Pharmaceuticals Incorporated | $18.54 | 1 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| INNOVAMATRIX AC Normalized: innovamatrix ac |
Device | ConvaTec Inc. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| VersaWrap Normalized: versawrap |
Device | Alafair Biosciences, Inc. | $3.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 116 | 33 |
| Eliquis | Apixaban | 62 | 16 |
| Xarelto | Rivaroxaban | 62 | 18 |
| Atorvastatin Calcium | Atorvastatin Calcium | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | 16 |
| Cilostazol | Cilostazol | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,880.15 · 80 records | Boston Scientific Corporation | ARTEGRAFT VASCULAR GRAFT, ARTIX MT, AngioJet Ultra 5000A, Assure WCD, BodyGuardian, CARTO 3, CLOT MANAGEMENT, CLOTTRIEVER BOLD CATHETER, CT THROMBECTOMY SYSTEM KIT, CellerateRX, ELUVIA, ENDOCROSS Device, ENDURANT IIS, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent, Exparel, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, Flexitouch Plus, HEMOBLAST BELLOWS, INNOVAMATRIX AC, Indigo System, Miro3D, Nimbl, Pico 14, Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System, RESONATE EL ICD VR, Sotalol Hydrochloride, Sublime 014 Rx PTA Balloon Dilatation Catheter, Sublime Microcatheter, 018, 200cm, Straight, TREO ABDOMINAL STENT-GRAFT SYSTEM, Torus Stent Graft System, VersaWrap, Versajet, ZENITH SPIRAL-Z, ZILVER PTX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error